- Approval Id
- 59287d4cbc10fd27
- Drug Name
- DERMOVATE SCALP APPLICATION 0.05% W/W
- Product Name
- DERMOVATE SCALP APPLICATION 0.05% W/W
- Approval Number
- SIN04499P
- Approval Date
- 1990-05-23
- Registrant
- GLAXOSMITHKLINE PTE LTD
- Licence Holder
- GLAXOSMITHKLINE PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- PRESCRIPTION ONLY MEDICINES
- Dosage Form
- LOTION
- Dosage
- <p><strong>Dosage and Administration</strong></p>
<p>Pharmaceutical form: Scalp Application</p>
<p>Apply sparingly to the scalp night and morning until improvement occurs. As with other highly-active topical steroid preparations, therapy should be discontinued when control is achieved. Repeated short courses of <em>DERMOVATE</em> Scalp Application may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used.</p>
<p>Avoid contact with the eyes. Hands should be washed after application.</p>
<p>Due to the flammable nature of <em>DERMOVATE</em> Scalp Application, patients should avoid smoking or being near an open flame during application and immediately after use.</p>
<p><strong>Children</strong></p>
<p>Children are more likely to develop local and systemic side effects of topical corticosteroids and, in general, require shorter courses and less potent agents than adults.</p>
<p>Care should be taken when using clobetasol propionate to ensure the amount applied is the minimum that provides therapeutic benefit.</p>
<p>Clobetasol propionate is contraindicated in children under 1 year of age.</p>
<p><strong>Elderly</strong></p>
<p>The greater frequency of decreased hepatic or renal function in the elderly may delay elimination if systemic absorption occurs. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.</p>
<p><strong>Renal / Hepatic Impairment</strong></p>
<p>In case of systemic absorption (when application is over a large surface area for a prolonged period) metabolism and elimination may be delayed therefore increasing the risk of systemic toxicity. Therefore, the minimum quantity should be used for the shortest duration to achieve the desired clinical benefit.</p>
- Route Of Administration
- TOPICAL
- Indication Info
- <p><strong>Indications</strong></p>
<p>Steroid responsive dermatoses of the scalp such as:</p>
<ul class="dash">
<li>Psoriasis</li>
<li>Recalcitrant eczemas</li>
</ul>
- Contraindications
- <p><strong>Contraindications</strong></p>
<p>The following conditions should not be treated with <em>DERMOVATE</em></p>
<ul>
<li>Hypersensitivity to clobetasol, or to any of the excipients in the preparation</li>
<li>Infections of the scalp</li>
</ul>
<p><em>DERMOVATE</em> is contraindicated in dermatoses in children under one year of age, including dermatitis.</p>
- Atc Code
- D07AD01
- Atc Item Name
- clobetasol
- Pharma Manufacturer Name
- GLAXOSMITHKLINE PTE LTD
- Company Detail Path
- /organization/glaxosmithkline-pte-ltd
